Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients

Clinical Pharmacokinetics

Volumn 57, Issue 8, 2018, Pages 989-1000

  Cojutti, Piergiorgio ^a,b   Pai, Manjunath P ^c   Pea, Federico ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BISOPROLOL; CARBAMAZEPINE; CREATININE; DEXAMETHASONE; LINEZOLID; METHYLPREDNISOLONE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; RIFAMPICIN; ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MONITORING; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FEMALE; FIRST ORDER RATE CONSTANT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM CONCENTRATION; MAXIMUM PERMISSIBLE DOSE; MEDICAL PARAMETERS; MICHAELIS CONSTANT; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBESITY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROBABILITY OF TARGET ATTAINMENT; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; BODY MASS; DOSE RESPONSE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; LINEZOLID; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES;

EID: 85032364249     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-017-0606-5     Document Type: Article

References (31)

1. NCD Risk Factor Collaboration. (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377–96.
2. GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
3. Gallus S, Lugo A, Murisic B, Bosetti C, Boffetta P, La Vecchia C. Overweight and obesity in 16 European countries. Eur J Nutr. 2015;54(5):679–89.
4. An R. Prevalence and trends of adult obesity in the US, 1999–2012. ISRN Obes. 2014;2014:185132.
5. Micciolo R, Canal L, Minniti A, Mazzali G, Fantin F, Corzato F, et al. The association between excess weight and comorbidity and self-rated health in the Italian population. Ann Epidemiol. 2013;23(4):172–8.
6. Dobner J, Kaser S. Body mass index and the risk of infection—from underweight to obesity. Clin Microbiol Infect. 2017. doi:10.1016/j.cmi.2017.02.013.
7. Purrello SM, Garau J, Giamarellos E, Mazzei T, Pea F, Soriano A, et al. Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options. J Glob Antimicrob Resist. 2016;7:178–86.
8. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136–45.
9. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54(11):4605–10.
10. Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121(4):303–8.
11. Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48(6):728–31.
12. Tsuji Y, Holford NHG, Kasai H, Ogami C, Heo YA, Higashi Y, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol. 2017;83(8):1758–72.
13. Taubert M, Zoller M, Maier B, Frechen S, Scharf C, Holdt LM, et al. Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients. Antimicrob Agents Chemother. 2016;60(9):5254–61.
14. Minichmayr IK, Schaeftlein A, Kuti JL, Zeitlinger M, Kloft C. Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients. Clin Pharmacokinet. 2017;56(6):617–33.
15. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.
16. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013;57(3):1144–9.
17. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–23.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
19. Peng GW, Stryd RP, Murata S, Igarashi M, Chiba K, Aoyama H, et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal. 1999;20(1–2):65–73.
20. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467–76.
21. Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58(4):2334–43.
22. Mendes RE, Hogan PA, Jones RN, Sader HS, Flamm RK. Surveillance for linezolid resistance via the Zyvox(R) annual appraisal of potency and spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. J Antimicrob Chemother. 2016;71(7):1860–5.
23. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47(2):548–53.
24. Plock N, Buerger C, Joukhadar C, Kljucar S, Kloft C. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos. 2007;35(10):1816–23.
25. Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242–7.
26. Young JF, Luecke RH, Pearce BA, Lee T, Ahn H, Baek S, et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxicol Environ Health A. 2009;72(8):527–40.
27. Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother. 2015;70(1):198–206.
28. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034–42.
29. Pea F, Cadeo B, Cojutti PG, Pecori D, Bassetti M. Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report. Ther Drug Monit. 2014;36(5):687–9.
30. Cojutti P, Crapis M, Bassetti M, Hope W, Pea F. Linezolid underexposure in a patient co-treated with venlafaxine. Eur J Clin Pharmacol. 2015;71(10):1285–6.
31. Ashizawa N, Tsuji Y, Kawago K, Higashi Y, Tashiro M, Nogami M, et al. Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. J Infect Chemother. 2016;22(5):331–4.